Canadian Nuclear Research Initiative: Health (CNRI-H)

Canadian Nuclear Laboratories’ (CNL) Canadian Nuclear Research Initiative-Health Program (CNRI-H) is a program developed by CNL to further the realization of its mission of contributing to the health of Canadians. Through CNRI-H, CNL provides financial support¹ along with its expertise, experience, capabilities and makes this available and accessible to the healthcare community to advance new life saving radiopharmaceutical solutions. CNRI-H is a turnkey solution that integrates both funding and project execution in one award.

The focus of the program is Radiopharmaceutical Therapy optimization, Toxicology and Pre-clinical Evaluation research. The goal of the program is to accelerate the optimization of therapeutic isotopes production and  the  clinical translation of targeted radiopharmaceuticals for the benefit of Canadians whilst increasing the safety and efficacy of therapies that involve radiopharmaceuticals.

CNL will be working with the selected third-party proponents in Canada and internationally on projects to be delivered as contract research. CNL would be financially supporting these projects by contributing significantly to the project cost as a matching grant in-kind (cost sharing details are elaborated in section 2.1).

Annually, CNL will issue CNRI-H call for proposals (CFP), review the proposals received and select the proposals that fall within defined preselection criteria. CNL will then proceed to formalize agreements with the selected party (ies) to deliver the project(s). CNL does not intend to share in the ownership of R&D deliverables under the CNRI-H program. Project execution will begin in May 2024 and may continue for a maximum of 24 months.

For more information, or to submit your proposal, email commercial@cnl.ca.

CNRI Program Timeline